An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of RO7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy

Trial Profile

An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of RO7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Risdiplam (Primary)
  • Indications Spinal muscular atrophy
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Acronyms Jewelfish
  • Sponsors Roche
  • Most Recent Events

    • 31 Oct 2018 Planned number of patients changed from 24 to 125.
    • 27 Apr 2018 Planned primary completion date changed from 5 Apr 2019 to 1 Dec 2020.
    • 23 Apr 2018 Planned End Date changed from 5 Apr 2019 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top